Synchron will use the additional $200 million to run a clinical trial that could support regulatory approval in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback